Pfizer Inc is intensifying its focus on India, targeting the country as a key growth market for cancer drugs, obesity therapies, vaccines, and specialty medicines. The move comes as the U.S. pharmaceutical giant seeks to rebuild momentum following the decline of COVID-era sales. Meenakshi Nevatia, Pfizer India's country president, described India as a "must-win" market, emphasizing the need to launch products more quickly and price them for local conditions. The company aims to leverage India's growing healthcare demand to offset patent cliffs and generic competition.
Financial Performance and Market Reaction
Pfizer reported first-quarter revenue of $14.5 billion, a 5% increase year-over-year. Excluding older drugs, newer and acquired treatments saw a 22% operational jump. However, the company faces a $1.5 billion revenue hit this year from generics and biosimilars. Shares fell 1.8% to $25.29 in New York trading, bringing the market capitalization to approximately $144.9 billion. Analysts remain cautious; J.P. Morgan's Chris Schott noted the potential for a more compelling narrative as the pipeline develops, but investors are waiting for stronger clinical data. RBC analyst Trung Huynh described Pfizer as "a catalyst story, not an earnings story."
India Strategy and Local Manufacturing
Access is as critical as science in Pfizer's India push. Nevatia highlighted that nearly 70% of Pfizer's local sales come from products manufactured in India. The company is closely monitoring the obesity market while navigating Indian clinical requirements for new offerings. Price sensitivity, delays from local studies, and regulatory hurdles could slow adoption, but Pfizer sees India as a vital piece of its global growth puzzle.
Regulatory Win in Europe for Hympavzi
Pfizer scored a regulatory success in Europe, where the European Commission expanded approval for Hympavzi, a once-weekly hemophilia treatment. The approval now covers adults and adolescents aged 12 and older with hemophilia A or B who have developed inhibitors—antibodies that interfere with standard factor-replacement therapies. Data from the Phase 3 BASIS trial showed a 93% reduction in the mean treated annualized bleeding rate compared to on-demand therapy. "The patient journey can be complex and challenging with limited options available today," said Alexandre de Germay, an executive at Pfizer.
Competitive Landscape in Hemophilia
Hemophilia A and B result from inherited deficiencies of clotting proteins. Hympavzi, a weekly subcutaneous injection, works by blocking tissue factor pathway inhibitor (TFPI), a protein that regulates blood clotting. The market is crowded: Sanofi's Qfitlia received U.S. approval in 2025 for routine prophylaxis in hemophilia A or B regardless of inhibitor status, while Novo Nordisk's Alhemo is approved for patients aged 12 and older with inhibitors.
Obesity Market Challenges
Obesity remains a major opportunity, but Pfizer is behind competitors. Its initial obesity candidate, acquired through the Metsera deal, is not expected to launch before 2028 even if trials succeed. That timeline places Pfizer well behind Eli Lilly and Novo Nordisk, whose GLP-1 therapies have reshaped investor expectations in the space.
Risks and Outlook
Pfizer faces multiple risks: price sensitivity in India, potential delays from local studies, and regulatory approvals that may not translate into quick adoption. For Hympavzi, commercial outcomes are uncertain, and thrombosis was the most serious adverse event in clinical trials. Investors are looking for tangible sales growth, not just pipeline promises. Pfizer's next moves—cracking India, advancing in obesity, cancer, vaccines, and niche drugs like Hympavzi—will determine whether the company can regain investor confidence.
